In long-term, VLA-4 inhibition or the additional targeting of BCR pathway molecules (e.g., by other inhibitors of PI3K than idelalisib to avoid its severe side effects [49]) might be explored as additions to ibrutinib therapy for high-risk CD49d-high CLL patients. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.